Fibroblast growth factor 23 and the heart

Christian H Faul

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose of review: Elevated serum levels of the phosphaturic hormone fibroblast growth factor 23 (FGF23) are strongly associated with chronic kidney disease (CKD) progression and mortality, and are also independently associated with left ventricular hypertrophy, a major contributor to cardiovascular disease (CVD) and death in CKD patients. As FGF23 levels rise long before serum phosphate in CKD, FGF23 is a more sensitive biomarker of disordered phosphate metabolism and its associated renal and CVD toxicity. Recent findings: This review will address the novel possibility that FGF23 contributes directly to CVD in patients with CKD. We will summarize the basic principles of FGF-mediated signal transduction and review the current literature on effects of FGF family members on the heart as well as FGF23 signaling in 'classic' target cells, in order to flesh out the novelty underlying FGF23-induced cell signaling in the heart. By doing so we will speculate on why such a direct cardiac effect has not been described before, and suggest a novel target for pharmacological intervention. Summary: By demonstrating direct pathological effects of FGF23 on the heart, novel findings from a recent translational study reposition FGF23 from biomarker of risk, to mechanism of disease. Therefore the pharmacological interference with FGF23 and/or its cardiac receptor in CKD patients could be beneficial to prevent or treat CVD.

Original languageEnglish
Pages (from-to)369-375
Number of pages7
JournalCurrent Opinion in Nephrology and Hypertension
Volume21
Issue number4
DOIs
StatePublished - Jul 1 2012

Fingerprint

Chronic Renal Insufficiency
Cardiovascular Diseases
Biomarkers
Phosphates
Pharmacology
fibroblast growth factor 23
Left Ventricular Hypertrophy
Serum
Disease Progression
Signal Transduction
Hormones
Kidney
Mortality

Keywords

  • calcineurin
  • cardiorenal syndrome
  • fibroblast growth factor receptor signaling
  • left ventricular hypertrophy

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

Fibroblast growth factor 23 and the heart. / Faul, Christian H.

In: Current Opinion in Nephrology and Hypertension, Vol. 21, No. 4, 01.07.2012, p. 369-375.

Research output: Contribution to journalArticle

Faul, Christian H. / Fibroblast growth factor 23 and the heart. In: Current Opinion in Nephrology and Hypertension. 2012 ; Vol. 21, No. 4. pp. 369-375.
@article{6a4e51326e7e4e83817fcdc95c296559,
title = "Fibroblast growth factor 23 and the heart",
abstract = "Lippincott Williams & Wilkins.",
keywords = "calcineurin, cardiorenal syndrome, fibroblast growth factor receptor signaling, left ventricular hypertrophy",
author = "Faul, {Christian H}",
year = "2012",
month = "7",
day = "1",
doi = "10.1097/MNH.0b013e32835422c4",
language = "English",
volume = "21",
pages = "369--375",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Fibroblast growth factor 23 and the heart

AU - Faul, Christian H

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Lippincott Williams & Wilkins.

AB - Lippincott Williams & Wilkins.

KW - calcineurin

KW - cardiorenal syndrome

KW - fibroblast growth factor receptor signaling

KW - left ventricular hypertrophy

UR - http://www.scopus.com/inward/record.url?scp=84862122363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862122363&partnerID=8YFLogxK

U2 - 10.1097/MNH.0b013e32835422c4

DO - 10.1097/MNH.0b013e32835422c4

M3 - Article

C2 - 22531163

AN - SCOPUS:84862122363

VL - 21

SP - 369

EP - 375

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 4

ER -